Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the...
Clinical trial results
Visen Pharmaceuticals Publishes Phase III Data for Lonapegsomatropin in Growth Hormone Deficiency
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...
Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study
China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...
Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies
Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...
HutchMed Announces Initial Results from FRUTIGA Phase III Study
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initial results from...
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...
3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint
China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...
Innovent Biologics’ Tafolecimab Shows Strong LDL-C Reduction in Phase III Study
China-based Innovent Biologics, Inc. (HKG: 1801) announced the results of the Phase III CREDIT-1 study...
Ascentage Pharma Presents APG-1387 Phase I Study Results at AASLD
Hong Kong-based biotech Ascentage Pharma (HKG: 6855) presented the Phase I clinical study results of...
Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH
Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...
RemeGen’s Telitacicept Shows Positive Results in Phase II Myasthenia Gravis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has released data from a Phase II...
China Grand’s STC3141 Reaches Primary Endpoint in ARDS Phase Ib Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib clinical study...
Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...
Covis Pharma’s COPD Therapies Show Positive Results in Phase III AVANT Trial
Luxembourg-based Covis Pharma Group has released positive topline data from its Phase III AVANT trial,...
MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...
Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778
China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I...
Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...